Ni-HIGH: A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer (UMIN-CTR) - Oct 2, 2026 - P1 | N=45 | Completed | Sponsor: The Cancer Institute Hospital of JFCR | Unknown status ➔ Completed | Phase classification: PN/A ➔ P1
Phase classification • Trial completion • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2
|